Evidence map›Paper›PMID 41684565›Full record

ArticleArchives of medical science : AMS2025

Camelliol C inhibits viability, migration, and invasion of human cervical cancer cells via induction of apoptosis, G2/M cell cycle arrest, and blocking of PI3K/AKT signalling pathway.

Na An, Feng Liu

Abstract read
In one paragraph

Article in Archives of medical science : AMS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Na AnDepartment of Obstetrics and Gynaecology, Shengli Oilfield Central Hospital, Dongying, Shandong, China.
Feng LiuDepartment of Obstetrics and Gynaecology, Shengli Oilfield Central Hospital, Dongying, Shandong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Cervical cancer is a devastating cancer and is currently ranked as the fourth most prevalent type of cancer in the world. The lack of efficacious chemotherapy forms a bottleneck in the treatment of cervical cancer. This study was therefore undertaken to evaluate the anticancer effects of camelliol C against human cervical cancer cells. Material and methods: Normal cell line (NCEC) and cervical cancer cell lines (Csdki, HeLa, C33A, and siHa) were used in this study. Cell viability was determined by MTT assay, and apoptosis was detected by DAPI and annexin V/PI staining. Cell cycle analysis, ROS, and MMP levels were examined by flow cytometry. Cell migration and invasion was monitored by transwell assays. Results: The results showed that camelliol C inhibits the proliferation of all the human cervical cancer cell lines with IC Conclusions: Camelliol C may prove beneficial in the treatment of cervical cancer.

Indexed as

apoptosiscamelliol Ccell cyclecervical cancerproliferation

Identifiers

PMID41684565
PMCPMC12892268

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.